Depression Clinical Trials in Newark

View 18 new treatments for depression near you in Newark, NJ near me. Every day, Power helps over 527 depression patients connect with leading medical research.
8
2
1
3
1
1
View 16 trials in Newark
Filter (16)

Psilocybin for Depression

Research Clinic, Princeton + 1 more

This trial is testing psilocybin, a substance from mushrooms, to see if it can help adults with depression who may not respond well to current treatments. Psilocybin works by affecting brain chemicals related to mood. Psilocybin has shown promise as a treatment for major depressive disorder and was designated as a breakthrough therapy by the FDA in 2019.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Cariprazine for Bipolar Disorder in Youth

AbbVie Clinic, Neptune + 3 more

This trial is testing the safety and effectiveness of Cariprazine for treating depressive episodes in children and teenagers with bipolar I disorder. The goal is to find out if Cariprazine can help young people with this condition. Cariprazine is an atypical antipsychotic recently approved for the treatment of depressive episodes in adults with bipolar I disorder.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director

Psilocybin for Major Depressive Disorder - TRD

COMPASS Pathways Clinic, Princeton + 1 more

This trial is testing COMP360, a new treatment for adults who have not responded to other depression treatments. Participants will receive one of three doses of COMP360 along with psychological support. The goal is to see if this combination can help improve their depression symptoms.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

NMRA-335140 for Depression

Neumora Clinic, Princeton + 1 more

This trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

NMRA-335140 for Depression

Neumora Clinic, Princeton + 1 more

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

ALTO-203 for Depression

Alto Neuroscience Clinic, Princeton + 1 more

The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.Show More
Recruiting
Phase 2
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

NMRA-335140 for Bipolar Depression

Neumora Clinic, Princeton + 1 more

This trial is testing a new medication called NMRA-335140 to see if it can help adults with Bipolar II disorder who are experiencing major depression. The medication aims to improve mood and reduce feelings of depression.Show More
Recruiting
Phase 2
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders

Research Clinic, Belle Mead + 1 more

The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is a viable adjunctive treatment of substance use treatments.Show More
Waitlist
N/A
Est. 4 - 6 Weeks
Michael R Grandner, PhD
Principal Investigator

Expressive Writing for Emotional Well-Being

Research Clinic, Princeton + 1 more

Expressive writing involves writing about one's deepest thoughts and feelings surrounding an emotional event. The current literature on the efficacy of expressive writing is mixed and warrants further investigation into how, when, and for whom expressive writing is an effective intervention. The goal of this study is to compare the efficacy of expressive writing interventions in young adults when people imagine that they're writing to themselves vs. a loved one. Participants will carry out an expressive writing exercise for 14 consecutive days. Participants are randomized into 3 groups: Self, Other, and Control. The Self group is instructed to write as if they were talking to themselves. The Other group is instructed to direct their writing to someone they feel close to. The Control group is asked to write down a factual description of their routine that day, and direct this writing to themselves. We will recruit participants until we have usable data from 53 participants per group (i.e., 159 in total).Show More
Recruiting
N/A
Est. 4 - 6 Weeks
Erik Nook, PhD
Principal Investigator

BeatIt-MV Therapy for Minimally Verbal Autistic Adults

Research Clinic, Piscataway + 1 more

The present study aims to adapt and evaluate the feasibility of the BeatIt-2 behavioral activation intervention for people with intellectual disabilities and low mood to be implemented with minimally verbal autistic individuals.Show More
Recruiting

No Placebo Trial

N/A
Est. 5 - 8 Weeks
Vanessa Bal, PhD
Principal Investigator
Page 1 of 2

Frequently Asked Questions

How much do depression clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do depression clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across depression trials in Newark, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for depression patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Why are others applying to these studies?

  • I have tried two other drugs that didn't have any positive affect on my mental health and am hoping that trying out this trial will help me find a solution.

    M.A. Patient

    Depression Patient

  • I've tried many anti-depressants in my 45 year struggle with Major Depression. I'm hoping this study is the 'game changer'

    B.E. Patient

    Late-Life Depression Patient

  • I've tried more then 5 drugs for depression and it's very depressing frustrating when they do not work, or even help nothing, I'm still looking for that one or 2 that will help

    A.L. Patient

    Major Depression Patient